SCHEMBL30049333

SCHEMBL30049333

CC(C)(C)CN1CCC2(CC1)CCN(S(=O)(=O)c1ccc(N3CCOC3=O)nc1)CC2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.42
▸ GAA P10253 4/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ LMNA P02545 3/20 0.38
▸ PKM P14618 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ CYP2D6 P10635 4/20 0.38
▸ TSHR P16473 2/20 0.37
▸ KCNJ1 P48048 3/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ USP2 O75604 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27161892 1.00 ALDH1A1 (0.42) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL27161681 0.91 ALDH1A1 (0.40) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL30049349 0.91 ALDH1A1 (0.40) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL27162476 0.90 CYP3A4 (0.42) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL30050972 0.90 CYP3A4 (0.42) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL30049828 0.85 ALDH1A1 (0.37) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL27161560 0.85 ALDH1A1 (0.37) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL30049383 0.84 CYP2D6 (0.53) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL27162693 0.84 CYP2D6 (0.53) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL30049755 0.83 CYP3A4 (0.41) ALDH1A1GAAKDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 ALDH1A1 1011/4885GAA 3700/4885KDM4E 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback